Acute Myeloid Leukemia test (RUO)
Qlucore Insights Acute Myeloid Leukemia (AML) test combine molecular subtype identification with cost efficient gene fusion detection for informed decision making - all in one test. In addition, the overexpression of the MECOM gene is indicated as this enables a more comprehensive detection of samples that potentially should be classified as the subtype MECOM-r.
Built on AI-based machine learning, standard lab-workflows and transcriptomics, the test opens new ways for fast, cost efficient and objective sample analysis utilizing both gene expression data and gene fusions.
Contact us to find out more
Current Routine Diagnostics of AML
Risk stratification in AML relies on a combination of genetic markers and clinical parameters. Today, laboratories typically need to run several separate assays to obtain this information. By consolidating multiple analyses into one software‑based test, Qlucore enables laboratories to streamline workflows and improve cost efficiency.
Performance (RUO)
The Qlucore Insights AML (RUO) classifier performs gene expression-based subtype classification of the groups listed below.
Sensitivity measured using nested cross validation on the training data set of 486 samples range from 0,60 for the challenging subtype MECOM-r to 0,99 and specificity starts at 0,95 for AML- MR and is 0,99 for most subtypes.
In addition, the overexpression of the MECOM gene is indicated as this enables a more comprehensive detection of samples that potentially should be classified as MECOM-r. The test lists all 30+ guideline mandated gene fusions in the report as well as novel gene fusions that match specified quality measurements.
The test detects the following subtypes:
- AML-MR
- CBFB::MYH11
- CEBPA bZIP
- MECOM-r
- KMT2A-r
- NPM1
- PML::RARA
- RUNX1::RUNX1T1
- TP53
Sample type: Fresh frozen
Reach out for more detailed information.